HCLTech Signs an Exclusive Preferred Professional Services Agreement With Cloud Software Group for TIBCO Solutions
HCLTech, a leading global technology company, announced an exclusive preferred professional services agreement with Cloud Software Group, to help implement, upgrade, modernize and provide services for all TIBCO products for enterprise customers across the globe. This partnership will help drive better value for end customers leveraging TIBCO products to further accelerate their data-driven digital transformation.
Cloud Software Group is the company formed upon completion of the Citrix take-private transaction and related combination with TIBCO. Today, Cloud Software Group provides the modern enterprise with mission-critical software through its key brands, including TIBCO, Citrix, NetScaler, Spotfire, XenServer, ShareFile, and Jaspersoft.
Cloud Software Group’s TIBCO customers will have access to enhanced digital transformation capabilities through HCLTech's technology offerings and consulting expertise across digital, cloud, automation, engineering and process optimization.
The addition of TIBCO products will further strengthen HCLTech’s professional services portfolio that already includes a comprehensive set of software product lines.
Close to 400 professional services employees from Cloud Software Group with expertise in TIBCO products will transition to HCLTech, bringing their deep domain knowledge to serve ongoing customer relationships and scale up HCLTech's existing TIBCO Center of Excellence.
“At Cloud Software Group, we’re constantly searching for opportunities to deliver an exceptional customer experience,” said Scott Harris, Senior Vice President, Cloud Software Group. “Through this partnership, we are enhancing and expanding how we support our TIBCO customers along their data journeys. With HCLTech’s long-standing history of expertise in innovation and cutting-edge digital technologies, we can further empower enterprises as they unlock the potential of real-time data through our platform.”
“This is a win-win partnership for both companies. We look forward to collaborating with Cloud Software Group’s product and support teams, adding yet another differentiator to our IT services portfolio,” said Anil Ganjoo, Chief Growth Officer, Americas, TMT and RCPG, HCLTech. “We look forward to an amazing journey with the new employees from Cloud Software Group and are thrilled to welcome them to HCLTech."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828017585/en/
Contact information
For further details, please contact:
HCLTech
Michelle Rico, Americas
michelle.rico@hcl.com
Elka Ghudial, EMEA
elka.ghudial@hcl.com
James Galvin, ANZ
james.galvin@hcl.com
Devneeta Pahuja, India and APAC
devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom